
Firmonertinib did not improve PFS in the phase 3 FURVENT trial in patients with EGFR Exon 20–Mutant NSCLC.
Anthony El-Khoueiry, MD, provides insight on the case of a 69-year-old man with stage 4 hepatocellular carcinoma and evaluates current and emerging treatment options.
Case: A 69-Year-Old Man with Stage 4 Hepatocellular Carcinoma
Initial presentation
Clinical workup
Treatment and Follow-Up






